Oppenheimer Asset Management Inc. Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

Oppenheimer Asset Management Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 31.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,950 shares of the medical research company's stock after selling 3,218 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in IQVIA were worth $1,225,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. American National Bank & Trust purchased a new stake in shares of IQVIA in the 1st quarter valued at $26,000. ST Germain D J Co. Inc. grew its position in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in IQVIA during the fourth quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth about $44,000. Finally, Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.4%

NYSE:IQV traded down $0.64 during midday trading on Friday, hitting $157.53. 2,309,431 shares of the company were exchanged, compared to its average volume of 1,644,207. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a market capitalization of $27.25 billion, a PE ratio of 21.46, a price-to-earnings-growth ratio of 1.75 and a beta of 1.28. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The company has a fifty day simple moving average of $149.26 and a 200 day simple moving average of $174.35.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business's revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.54 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on IQV shares. Barclays cut their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group decreased their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.